Gonadotropin releasing factor (GnRF) analogue-protein conjugate

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Improvac.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Improvac.

For practical information about using Improvac, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 05/04/2022

Authorisation details

Product details
Agency product number
Active substance
Synthetic peptide analogue of GnRF conjugated to diptheria toxoid
International non-proprietary name (INN) or common name
Gonadotropin releasing factor (GnRF) analogue-protein conjugate
  • Male pigs (from 8 weeks of age)
  • Female pigs (from 14 weeks of age)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve

Product information

20/01/2022 Improvac - EMEA/V/C/000136 - II/0036

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

Male pigs:
Induction of antibodies against GnRF to produce a temporary immunological suppression of testicular function. For use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. Another key contributor to boar taint, skatole, may also be reduced as an indirect effect. Aggressive and sexual (mounting) behaviours are also reduced.

Female pigs:
Induction of antibodies against GnRF to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
1 rating
2 ratings